ReviewGenes2026
Precision Medicine Through Network Language: Integrating Clinical Insight and Data Expertise.
Review in Genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The microbiome as a systems-level regulator of immune, metabolic, neural, and endocrine signaling in cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision medicine is facing a critical transition driven by the growing complexity of biological data and the insufficient ability of current models to translate such data into clinically meaningful information. Linear, single-gene approaches are no longer adequate to explain the multifactorial nature of most modern diseases, whose phenotypes emerge from combinations of genetic, molecular, and environmental factors. Network-based precision medicine addresses this by providing a systemic framework capable of integrating heterogeneous omics data, interactomes, and clinical information to identify disease modules and novel therapeutic opportunities. The distinct novelty of this review is its focus on the potential of "network language" as the primary driver for realizing precision medicine through professional collaboration. We argue that networks are not merely tools that achieve precision "per se"; rather, their transformative power lies in their ability to serve as a shared and interpretable interface grounded in network theory. By offering this common conceptual ground, the paradigm bridges the deep cultural and methodological gaps between clinicians and data analysts, enabling effective cooperation between figures with fundamentally different, and often divergent, backgrounds. Practical tools-such as biological network analysis and Molecular Tumor Boards-demonstrate how computational modeling and clinical expertise can be successfully combined to generate actionable insights. Ultimately, network-based precision medicine represents a decisive step toward reconstructing the patient's complexity and promoting a genuinely personalized clinical approach in which quantitative analysis and medical reasoning act synergistically through multidisciplinary integration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.